Literature DB >> 12911853

Niacin: a powerful adjunct to other lipid-lowering drugs in reducing plaque progression and acute coronary events.

Michael H Davidson1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12911853     DOI： 10.1007/s11883-003-0014-1

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN： 1523-3804            Impact factor:   5.113


× No keyword cloud information.
  19 in total

1.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III).

Authors: 
Journal:  JAMA       Date:  2001-05-16       Impact factor: 56.272

2.  Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease.

Authors:  B G Brown; X Q Zhao; A Chait; L D Fisher; M C Cheung; J S Morse; A A Dowdy; E K Marino; E L Bolson; P Alaupovic; J Frohlich; J J Albers
Journal:  N Engl J Med       Date:  2001-11-29       Impact factor: 91.245

Review 3.  Niacin: a therapeutic dilemma. "One man's drink is another's poison".

Authors:  R A Kreisberg
Journal:  Am J Med       Date:  1994-10       Impact factor: 4.965

4.  Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B.

Authors:  G Brown; J J Albers; L D Fisher; S M Schaefer; J T Lin; C Kaplan; X Q Zhao; B D Bisson; V F Fitzpatrick; H T Dodge
Journal:  N Engl J Med       Date:  1990-11-08       Impact factor: 91.245

5.  Niacin, but not gemfibrozil, selectively increases LP-AI, a cardioprotective subfraction of HDL, in patients with low HDL cholesterol.

Authors:  T Sakai; V S Kamanna; M L Kashyap
Journal:  Arterioscler Thromb Vasc Biol       Date:  2001-11       Impact factor: 8.311

6.  Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia.

Authors:  Moti L Kashyap; Mark E McGovern; Kathleen Berra; John R Guyton; Peter O Kwiterovich; Wayne L Harper; Phillip D Toth; Laurence K Favrot; Boris Kerzner; Stephen D Nash; Harold E Bays; Phillip D Simmons
Journal:  Am J Cardiol       Date:  2002-03-15       Impact factor: 2.778

7.  Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid.

Authors:  L A Carlson; G Rosenhamer
Journal:  Acta Med Scand       Date:  1988

8.  Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia.

Authors:  J R Guyton; A C Goldberg; R A Kreisberg; D L Sprecher; H R Superko; C M O'Connor
Journal:  Am J Cardiol       Date:  1998-09-15       Impact factor: 2.778

Review 9.  Effect of niacin on atherosclerotic cardiovascular disease.

Authors:  J R Guyton
Journal:  Am J Cardiol       Date:  1998-12-17       Impact factor: 2.778

10.  Efficacy and safety of an extended-release niacin (Niaspan): a long-term study.

Authors:  D M Capuzzi; J R Guyton; J M Morgan; A C Goldberg; R A Kreisberg; O A Brusco; J Brody
Journal:  Am J Cardiol       Date:  1998-12-17       Impact factor: 2.778
View more
  1 in total

1.  Extended release niacin-laropiprant in patients with hypercholesterolemia or mixed dyslipidemias improves clinical parameters.

Authors:  Helen Vosper
Journal:  Clin Med Insights Cardiol       Date:  2011-09-19
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.